Piperlongumine inhibits cell growth and enhances TRAIL-induced apoptosis in prostate cancer cells

Gorkem KISMALI; Ogunc MERAL; Tevhide SEL; Ahmet CEYLAN; Merve ALPAY; Merve ALPAY; Funda KOSOVA; Dilek Ulker CAKIR; Begum YURDAKOK-DIKMEN; Neslihan TASCENE

Return

Piperlongumine inhibits cell growth and enhances TRAIL-induced apoptosis in prostate cancer cells

Author: Gorkem KISMALI ¹ ; Ogunc MERAL ¹ ; Tevhide SEL ¹ ; Ahmet CEYLAN ² ; Merve ALPAY ² ; Merve ALPAY ³ ; Funda KOSOVA ⁴ ; Dilek Ulker CAKIR ⁵ ; Begum YURDAKOK-DIKMEN ⁶ ; Neslihan TASCENE ⁷
Author Information

1. Ankara University, Faculty of Veterinary Medicine, Department of Biochemistry
2. Ankara University, Faculty of Veterinary Medicine, Department of Histology and Embryology
3. Duzce University, Faculty of Medicine, Department of Biochemistry
4. Celal Bayar University, School of Health Services, Department of Biochemistry
5. Canakkale Onsekiz Mart University, Faculty of Medicine, Department of Medical Biochemistry
6. Ankara University, Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology
7. Republic of Turkey Ministry of Agriculture and Forestry
Publication Type:Journal Article
Keywords: Apoptosis; Piperlongumine; Prostate cancer; Tumor necrosis factor-related apoptosis-inducing ligand
From:Asian Pacific Journal of Tropical Biomedicine 2020;10(5):216-223
CountryChina
Language:Chinese
Abstract: Objective: To investigate whether piperlongumine can sensitize prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and trigger apoptosis in prostate cells. Methods: Human prostate cancer cell lines PC3, LNCaP, and VCaP were cultured with piperlongumine and TRAIL. Then, cell proliferation, migration, caspase activation, apoptotic protein expressions, and death receptor expressions were measured. Results: Piperlongumine inhibited cell proliferation at low doses (<10 μM) alone and in combination with TRAIL (25 ng/mL), induced apoptosis, and suppressed cyclooxygenase activation. Additionally, piperlongumine induced expression of death receptors which potentiated TRAIL-induced apoptosis in cancer cells but did not affect decoy receptors. Piperlongumine also downregulated tumor cell-survival pathways, inhibited colony formation and migration of cancer cells alone or in combination with TRAIL. The combination of piperlongumine with TRAIL was found to be synergistic. Conclusions: Our findings indicate that piperlongumine can sensitize cancer cells to TRAIL through the upregulation of death receptors and can trigger apoptosis with the downregulation of anti-apoptotic proteins.